Escolar Documentos
Profissional Documentos
Cultura Documentos
Auckland Cancer Society Research Centre, The University of Auckland, Auckland, New Zealand
Department of Physiology, University of Arizona, Tucson, AZ, USA
Edited by:
Annarosa Arcangeli, University of
Florence, Italy
Reviewed by:
Carine Michiels, University of Namur,
Belgium
Brion William Murray, Pfizer Oncology
Research Unit, USA
*Correspondence:
Kevin O. Hicks, Experimental
Therapeutics Group, Auckland Cancer
Society Research Centre, The
University of Auckland, 85 Park Road,
Auckland 1142, New Zealand
e-mail: k.hicks@auckland.ac.nz
INTRODUCTION
Prodrugs that are enzymatically converted to active metabolites
(effectors) within tumors are of interest for selective cancer therapy. Three different strategies have been explored for intra-tumor
prodrug activation: (1) xenobiotic metabolizing enzymes that are
highly expressed in specific tumors (1, 2); (2) exogenous enzymes
targeted to tumors using antibody (3), viral (4), or bacterial (5)
vectors; (3) endogenous enzymes that reduce prodrugs only under
the hypoxic conditions that prevail in tumors. Hypoxia-activated
prodrugs (HAP), which provide this third strategy, not only exploit
a generic feature that differentiates tumors from most normal tissues but also potentially overcome the resistance of hypoxic cells to
radiotherapy and many chemotherapy drugs (615). Several HAP
have been evaluated clinically (1619), including ongoing studies
with the nitro compounds TH-302 (20, 21), PR-104A [(2225);
administered as the corresponding phosphate ester PR-104] and
PR-610 (26). However, many questions remain as to how HAP
should be designed for optimal anticancer activity.
In the present study we utilize pharmacokinetic/
pharmacodynamic (PK/PD) models to explore relationships
www.frontiersin.org
Foehrenbacher et al.
METHODS
The generalized SR-PK/PD model calculates steady-state concentrations of oxygen, HAP, and effector as well as resulting cell killing
in digitized 3D tissue microregions using Greens function methods (35, 54, 56). We used two different tissue microregions that
were derived by mapping microvascular anatomy as well as direction and velocity of blood flow in a rat cremaster muscle (56)
(normal network) and a subcutaneous FaDu tumor xenograft
(57) (tumor network). The blood vessels are represented by
cylindrical segments and vessel walls are treated as part of the tissue
space. The model was implemented using a customized version of
the Greens function method written in Visual C++ (Microsoft
Visual Studio 2010 Express) (35, 58).
CALCULATION OF OXYGENATION
Convective transport of oxygen along vessel segments and diffusion into the surrounding tissue (represented as homogeneous
Foehrenbacher et al.
CALCULATION OF PHARMACOKINETICS
(1)
(2)
C e and C i are the extracellular and intracellular concentrations, respectively, of prodrug or effector (denoted by N = P or
E), i and e are the intra- and extracellular volume fractions
with e = 1 i , k tN are first order rate constants for cell transfer
between the extracellular and intracellular compartments, DN is
the effective diffusion coefficient of compound N, 52 is the Laplacian operator, k metN is the rate constant for drug metabolism and r
is the rate of metabolic production with rP = 0 and rate of effector
KO 2
kmetP,max
KO 2 + [O2 ]
(3)
where k metP,max and k metP are the prodrug activation rate constants under anoxia and at the O2 concentration [O2 ], respectively,
and KO2 is the O2 concentration for half-maximum prodrug
activation.
CALCULATION OF CELL KILLING
(4)
where AUCiE is the intracellular exposure (area under the intracellular concentration-time curve) to the effector and a is a proportionality constant (potency) equal to the reciprocal of the effector
AUC to produce a SP of 0.1 as measured by clonogenic cell survival.
We distinguish two cases: case 1, where potency a scales with
k metE , broadly representing irreversible inhibitors such as DNAalkylating agents for which an increase in reactivity has similar
effects on reaction with target and non-target nucleophiles (59, 60)
and case 2, where a is independent of k metE (broadly representing
reversible inhibitors). Case 1, where cell killing is proportional to
the reactivity of the effector is used throughout this study unless
noted otherwise.
To estimate cell SP after radiation treatment, the linearquadratic model was used as previously (35, 54). The SP from
Table 1 | O2 transport parameters used to model oxygenation in the FaDu tumor and the cremaster muscle microregions.
Parameter
Unit
Value for
FaDu
Description
Cremaster
mm3
0.12
0.091
nl/min
40.0
75.0
Total blood inflow to region = sum of blood flow in all feeding arterioles
Q/V
nl/min/mm3
333
824
pO2
mm Hg
40.0
50.0
P 50
mm Hg
38.0
38.0
3.0
3.0
0.5
0.5
N
C0
cm3 O2 /mm Hg
HD
0.4
0.4
Discharge hematocrit
3.1 105
3.1 105
O2 solubility
Krogh diffusion coefficient for O2 diffusion
DO2
cm3 O2 /cm/s/mm Hg
4.2 1010
9.4 1010
DO2
cm2 /s
1.4 105
3.0 105
O2 diffusion coefficient
M0
cm3 O2 /cm3 /s
5 104
9.5 104
KmO2
mm Hg
1.0
1.0
Parameters were as reported previously for the FaDu (35) and the cremaster muscle microregion (56) except that M0 in the cremaster region was adjusted to achieve
the required hypoxic fraction. The chosen M0 value is intermediate between the values previously used to represent mild and moderate levels of muscle activity (56).
These O2 transport parameters gave hypoxic fractions and median pO2 values (Figure 3) in the range measured for tumors and normal tissues in humans using O2
electrode histography (45).
www.frontiersin.org
Foehrenbacher et al.
both radiation and prodrug at each point of the tumor microregion was calculated from the sum of log (SP) due to drug and
radiation alone. Log cell kill was then calculated as
log cell kill = log(Average SP)
(5)
All animal studies were approved by the University of Auckland Animal Ethics Committee. Male NIH-III nude mice (NIHLystbg Foxn1nu Btkxid ; 1820 g body weight), derived from breeding
mice purchased from Charles River Laboratories (Wilmington,
MA, USA), were dosed i.v. with PR-104H. The dosing solution was
prepared fresh for each mouse by dilution of a stock solution of
PR-104H in acetonitrile with sterile saline (to <20% acetonitrile)
within 3 min of dosing to minimize loss of PR-104H in aqueous solution. At the dose volume of 0.005 ml/g the acetonitrile
dose was 755 mg/kg and the vehicle alone did not cause signs
of toxicity over the duration of the experiment. Blood was collected by cardiac puncture up to 3 min after cervical dislocation
as in (62). Plasma was prepared as described (63) and mixed with
three volumes of cold acidified methanol (methanol:ammonium
acetate:acetic acid 1000:3.5:0.2, v/w/v) ~6 min after cardiac puncture. Liver tissue was dissected within 3 min of blood sampling,
snap-frozen in liquid nitrogen, and stored at 80C along with
plasma samples. Frozen tissue was pulverized at liquid nitrogen
temperature using a BioPulverizer (BioSpec Products, USA),
transferred to tared tubes, weighed, vortex mixed for 30 s with an
equal volume of cold phosphate buffered saline and six volumes
of cold acidified methanol, and stored at 80C. For LC-MS/MS
analysis [as reported in Ref. (35)], tissue and plasma extracts
were centrifuged (13,000 g, 4C, 10 min) and supernatants were
mixed 1:1 with cold water containing 1 M PR-104H-d4 and 1 M
PR-104M-d4.
RESULTS
In order to identify optimal properties of HAP, we developed a
SR-PK/PD model that captures the key features of both Class I
and Class II HAP (Figure 2). This model is a generalized form
of our SR-PK/PD model for PR-104 (35), which, unlike earlier
SR-PK/PD models (31, 32, 54) accommodates diffusion and reaction of the effector and explicitly considers intra- and extracellular
compartments in order to represent the plasma membrane barrier to prodrug uptake and effector efflux. Our generalized model
assumes that the effector can be further converted to inactive products within the cell (defined by rate constant k metE ). The model
incorporates only one effector (unlike the two alkylating metabolites from PR-104A) and represents an idealized HAP that is not
a substrate for O2 -insensitive two-electron-reduction, which is an
off-target activation mechanism of some HAP including PR-104A
(51). We also ignore any systemic generation of effector outside
the modeled tissue region, such as from hepatic metabolism.
TISSUE MICROREGIONS USED FOR SR-PK/PD MODELING
Our previous SR-PK/PD model for Class I HAP showed that high
prodrug activation rates limit killing of hypoxic cells by impairing tissue penetration of the prodrug (54). To investigate whether
this also applies to HAP with bystander effects and/or activation
restricted to more severe hypoxia (low KO2 ), we modulated the
Foehrenbacher et al.
www.frontiersin.org
Foehrenbacher et al.
Foehrenbacher et al.
Value
Unit
Description
AUCP inflow
50.0
M/h
k met P,max
0.01
s1
Maximum rate constant for metabolism of prodrug to effector (under anoxic conditions)
KO2
M; M
0.01
s1
K tP
K tE
0.1
0.01
s1
Rate constants for transfer from the extracellular to the intracellular compartment (k tN ) for
s1
DP
DE
106
cm2 /s
Tissue diffusion coefficients for prodrug and effector. Reported values are the
106
cm2 /s
0.4
k metE
0.200
M1 h1
0.0414
M1 h1
0.0663
Gy1
Proportionality constants for the linear-quadratic model for radiosensitivity under hypoxia
0.0028
Gy2
OER = OER
2.8
Kms
4.2
Dr
15
Gy
Radiation dose
Maximal O2 enhancement ratios for the and components of the linear-quadratic model (91)
The parameter and variables are similar to those estimated for our previous SR-PK/PD model for PR-104 in SiHa tumors (35).
www.frontiersin.org
Foehrenbacher et al.
prodrug + radiation and log cell kill by radiation alone. (C) Average
HAP-mediated killing in a hypothetical normal tissue in which cells are
assumed to have the same intrinsic sensitivity as tumor cells, based on
simulations in a microvascular network of a mapped rat cremaster muscle
region. (D) Tumor:normal tissue ratio of cell killing.
Foehrenbacher et al.
DISCUSSION
In this study, SR-PK/PD modeling was utilized to identify strategies for optimization of HAP. The model has a solid biological
foundation because it is based on our previous SR-PK/PD model
for PR-104 for which parameters have been determined experimentally using three cell lines (35). The latter model was the first
to explicitly consider the intra-tumor distribution of bystander
metabolites.
NORMAL TISSUE TOXICITY
www.frontiersin.org
A novel feature of the present study is the comparison of predictions for a tumor and normal tissue network, the latter based on
a mapped microvascular network in a rat cremaster muscle (56)
with oxygen consumption rate adjusted to simulate mild hypoxia
(Figure 3). This comparison is important because the utility of
HAP is likely to be constrained by the requirement that prodrug
activation at intermediate O2 does not cause toxicity in tissues
with physiological hypoxia, such as liver (4345), retina (66), and
possibly bone marrow (49). The low tumor:normal tissue ratios
of killing determined in our study (Figures 5, 7, and 8) point to
limitations on achieving tumor selectivity with HAP. However, it
is important to note that our model makes the assumption that
intrinsic cellular sensitivity to the released effector (potency parameter a) is the same for cells in the tumor and normal tissue
networks. Most effectors of HAP in clinical development are DNAreactive cytotoxins (13) that provide some tumor-specificity due to
the cytokinetics and DNA repair abnormalities (67) of tumor cells
relative to normal cells. In addition, release of HAP effectors that
target oncogenic pathways in tumor cells has potential for conferring additional tumor selectivity (68). Normal tissue models will
need to be revisited when more quantitative information about
oxygenation and drug targets in potentially dose-limiting normal
tissues is available. Nevertheless, the present results emphasize the
importance of using HAP strategies to augment selectivity of effectors that already provide some level of tumor selectivity, rather
than as the sole mechanism of tumor targeting.
In addition, normal tissue toxicity due to washout of effectors
has been a concern in the development of targeted anticancer prodrugs (69, 70) although to our knowledge no clear link between
toxicity and increased effector levels has been established. In the
current study systemic toxicity of HAP as a result of release of
active metabolites from the tumor appears unlikely; our model
suggests that a significant contribution to toxicity would require a
combination of extreme assumptions (high tumor burden, intratumor activation rates, effector stability, tumor blood flow rates, as
well as low systemic CL of effector). However, toxicity in normal
tissue sharing a microcirculatory system with the tumor remains
a possibility.
OPTIMAL PRODRUG PARAMETERS OF CLASS I AND CLASS II HAP
This study compared an idealized Class I HAP (high KO2 with nobystander effect, illustrated by tirapazamine and SN30000) and
a Class II HAP (low KO2 with bystander effect, e.g., PR-104A
and TH-302) to assess which of these HAP strategies is better
suited for complementation of radiotherapy. Our previous tirapazamine SR-PK/PD model showed that Class I HAP exhibit an
optimum k metP,max , above which hypoxic cell killing decreases
Foehrenbacher et al.
because increasing consumption of the prodrug limits its penetration to hypoxic regions (54). This finding could be replicated using
the present model, in which intra- and extracellular compartments
are made explicit (Figure 5). In contrast, activity of Class II HAP
was predicted to increase monotonically with increasing k metP,max
in the investigated range of 0.0011 s1 ; we consider this range to
be physiologically and pharmacologically relevant based on measured rate constants (32, 35, 54, 60). In addition, the potential
to further increase k metP,max by drug design would be limited by
membrane transport and by the concurrent decrease in tumor
selectivity (Figure 5D).
The superiority of Class II over Class I HAP at high k metP,max
can be explained by two factors. Firstly, the lower KO2 value minimizes metabolic loss during diffusion into hypoxic target regions
Foehrenbacher et al.
estimated by the SR-PK/PD model with modulation of (A) k met P, max , (B) k met E ,
(C) k t E , and (D) DE , with unmodulated parameters held at their default values
from Table 2, except in (D) where 10-fold higher values for k t E was used.
www.frontiersin.org
Foehrenbacher et al.
Foehrenbacher et al.
perfusion in tumors (78). This heterogeneity results in macroregional variations in oxygenation and prodrug delivery that may
decrease the overall relevance of bystander effects of Class II
HAP. For example, macroscopic, well-perfused, and oxygenated
areas [observed in some tumor xenografts (35, 79, 80)] would be
beyond the reach of the hypoxia-driven bystander effects studied
here, unless there is redistribution of diffusible effectors between
differently oxygenated tumor regions via the bloodstream (bloodborne bystander effect). Mapped tumor regions of a larger scale
are not yet available but could be used to investigate these macroregional effects in the future. Secondly, our steady-state model does
not account for time-dependent processes such as cycling hypoxia
(8183) and the kinetics of reoxygenation, cell proliferation, and
cell death. Cycling hypoxia is thought to arise from variations in
blood flow (8486), which would affect not only delivery of oxygen but also that of the HAP. Since cycling hypoxia has a dominant
periodicity of two to three cycles per hour (82), it may be relevant even for HAP with a residence time in the circulation of few
hours and critically important for HAP with long residence times
in tumors as is reoxygenation for effectors with long residence
times such as AQ4N (87). The implications of variable blood flow
and cycling hypoxia should be incorporated in future SR-PK/PD
models.
CONCLUSION
In spite of its limitations, the SR-PK/PD model has identified
strategies for optimization of HAP worthy of further investigation. This is the first modeling study that attempts to systematically
compare the activity of Class I and Class II HAP and the first that
integrates the use of a normal tissue network to assess tumor selectivity. It suggests that class II HAP offer the following advantages
relative to class I HAP: they tolerate a wider range of k metP,max
www.frontiersin.org
Foehrenbacher et al.
AUTHOR CONTRIBUTIONS
Tumor
WT
80.2
3.37
11.77
sPOR#6 300
14.4
48.7
WT
2.02
7.06
()/released (+) by a
sPOR#6 180
8.61
29.2
2.6a
2.8b
2.8b,c
ACKNOWLEDGMENTS
5.0d
44b
20b,c
0.286
0.00179
0.0140
0.00759
0.0578
microregion (pmol/mm3 )
48.1
CL (l/h/kg)
Free AUC extracted
WT
()/released (+) by a
sPOR#6 1.07
SUPPLEMENTARY MATERIAL
61.5
1.30
0.71
Using our previous PR-104 SR-PK/PD model for HCT116/WT tumors and
Estimated for CD-1 mice following i.v. administration of 56.2 mol/kg PR-104A
(92).
b
REFERENCES
in NIH-III nude mice after i.p. administration of 562 mol/kg PR-104 (35).
Tumor
Systemic effector
activitya
selectivityb
releasec
HAP
HAP+
only
radiation
k metP,max
k metE (case 1)
k metE (case 2)
DE
k tE
Overall cell kill predicted in the 3D FaDu tumor microregion (see Figures 5 and 7).
Ratio of overall cell killing in the tumor and cremaster muscle microregions (see
Overall effector released into the circulation by the FaDu tumor microregion (see
Figure 8).
1. Graaf MM, Boven E, Scheeren HW, Haisma HJ, Pinedo HM. Betaglucuronidase-mediated drug release. Curr Pharm Des (2002) 8:1391403.
doi:10.2174/1381612023394485
2. Jamieson D, Wilson K, Pridgeon S, Margetts JP, Edmondson RJ, Leung HY, et al.
NAD (P) H: quinone oxidoreductase 1 and NRH: quinone oxidoreductase 2
activity and expression in bladder and ovarian cancer and lower NRH: quinone
oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide
polymorphism. Clin Cancer Res (2007) 13:1584. doi:10.1158/1078-0432.CCR06-1416
3. Bagshawe KD. Antibody-directed enzyme prodrug therapy (ADEPT) for cancer.
Expert Rev Anticancer Ther (2006) 6:142131. doi:10.1586/14737140.6.10.1421
4. Duarte S, Carle G, Faneca H, de Lima MC, Pierrefite-Carle V. Suicide gene
therapy in cancer: where do we stand now? Cancer Lett (2012) 324:16070.
doi:10.1016/j.canlet.2012.05.023
5. Lehouritis P, Springer C, Tangney M. Bacterial-directed enzyme prodrug therapy. J Control Release (2013) 170:12031. doi:10.1016/j.jconrel.2013.05.005
6. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities
(and problems) for cancer therapy. Cancer Res (1998) 58:140816.
7. Rauth AM, Melo T, Misra V. Bioreductive therapies: an overview of drugs and
their mechanisms of action. Int J Radiat Oncol Biol Phys (1998) 42:75562.
doi:10.1016/S0360-3016(98)00302-2
8. Stratford IJ, Workman P. Bioreductive drugs into the next millennium. Anticancer Drug Des (1998) 13:51928.
9. Wardman P. Electron transfer and oxidative stress as key factors in the design
of drugs selectively active in hypoxia. Curr Med Chem (2001) 8:73961.
doi:10.2174/0929867013372959
Foehrenbacher et al.
10. Brown JM, Wilson WR. Exploiting tumor hypoxia in cancer treatment. Nat Rev
Cancer (2004) 4:43747. doi:10.1038/nrc1367
11. Rockwell S, Dobrucki IT, Kim EY, Marrison ST, Vu VT. Hypoxia and radiation therapy: past history, ongoing research, and future promise. Curr Mol Med
(2009) 9:44258. doi:10.2174/156652409788167087
12. Brown M, Henry S. Kaplan distinguished scientist award lecture 2007. The
remarkable yin and yang of tumour hypoxia. Int J Radiat Biol (2010) 86:90717.
doi:10.3109/09553002.2010.492492
13. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer (2011)
11:393410. doi:10.1038/nrc3064
14. Wilson WR, Hicks KO, Wang J, Pruijn FB. Prodrug strategies for targeting
tumour hypoxia. In: Melillo G, editor. Hypoxia and Cancer: Biological Implications and Therapeutic Opportunities. New York: Springer (2013). 283 p.
15. Hay MP, Hicks KO, Wang J. Hypoxia directed drug strategies to target the tumour
microenvironment. In: Koumenis C, Hammond E, Giaccia A, editors. Tumour
Microenvironment and Cellular Stress. New York: Springer (2014). 111 p.
16. Haffty BG, Wilson LD, Son YH, Cho EI, Papac RJ, Fischer DB, et al. Concurrent
chemo-radiotherapy with mitomycin C compared with porfiromycin in squamous cell cancer of the head and neck: final results of a randomized clinical trial.
Int J Radiat Oncol Biol Phys (2005) 61:11928. doi:10.1016/j.ijrobp.2004.07.730
17. Papadopoulos KP, Goel S, Beeram M, Wong A, Desai K, Haigentz M, et al.
A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated
prodrug AQ4N in patients with advanced malignancies. Clin Cancer Res (2008)
14:71105. doi:10.1158/1078-0432.CCR-08-0483
18. Rischin D, Peters LJ, OSullivan B, Giralt J, Fisher R, Yuen K, et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase
III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol (2010)
28:298995. doi:10.1200/JCO.2009.27.4449
19. McKeown SR, Cowen RL, Williams KJ. Bioreductive drugs: from concept to
clinic. Clin Oncol (2007) 19:42742. doi:10.1016/j.clon.2007.03.006
20. Ganjoo KN, Cranmer LD, Butrynski JE, Rushing D, Adkins D, Okuno SH, et al.
A phase I study of the safety and pharmacokinetics of the hypoxia-activated
prodrug TH-302 in combination with doxorubicin in patients with advanced
soft tissue sarcoma. Oncology (2011) 80:506. doi:10.1159/000327739
21. Borad MJ, Reddy S, Uronis H, Sigal DS, Cohn AL, Schelman WR, et al. Randomized phase II study of the efficacy and safety of gemcitabine + TH-302
(G+T) vs gemcitabine (G) alone in previously untreated patients with advanced
pancreatic cancer (Abstract LB-121). AACR Annual Meeting, Chicago (2012).
22. Jameson MB, McKeage MJ, Ramanathan RK, Rajendran J, Gu Y, Wilson WR,
et al. Final results of a phase Ib trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, in combination with gemcitabine or docetaxel in patients
with advanced solid tumors [abstract]. J Clin Oncol (2010) 28:2554.
23. McKeage MJ, Gu Y, Wilson WR, Hill A, Amies K, Melink TJ, et al. A phase I trial
of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly
to solid tumour patients. BMC Cancer (2011) 11:432. doi:10.1186/1471-240711-432
24. McKeage MJ, Jameson MB, Ramanathan RK, Rajendran J, Gu Y, Wilson WR,
et al. PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours. BMC Cancer
(2012) 12:496. doi:10.1186/1471-2407-12-496
25. Arana Yi GY, Borthakur G, Thall PF, Coveler AL, Ravandi F, Jabbour E, et al.
Final report of phase I/II study of PR104, a hypoxia-activated pro-drug, in
relapsed/refractory acute leukemia. J Clin Oncol (2013) 31(Suppl):7074.
26. Smaill JB, Jaiswal JK, Abbattista MR, Lu G-L, Anderson RF, Ashoorzadeh A, et al.
Mechanism of action of the hypoxia-activated irreversible pan-HER inhibitor
SN29966. Mol Cancer Ther (2011) 10:A247. doi:10.1158/1535-7163.TARG-11A247
27. Yin J, Glaser R, Gates KS. On the reaction mechanism of tirapazamine reduction
chemistry: unimolecular N-OH homolysis, stepwise dehydration, or triazene
ring-opening. Chem Res Toxicol (2012) 25:63445. doi:10.1021/tx200546u
28. Shinde SS, Maroz A, Hay MP, Patterson AV, Denny WA, Anderson RF. Characterization of radicals formed following enzymatic reduction of 3-substituted
analogues of the hypoxia-selective cytotoxin 3-amino-1,2,4-benzotriazine 1,4dioxide (tirapazamine). J Am Chem Soc (2010) 132:25919. doi:10.1021/
ja908689f
29. Wilson WR, Hicks KO, Pullen SM, Ferry DM, Helsby NA, Patterson AV.
Bystander effects of bioreductive drugs: potential for exploiting pathological
www.frontiersin.org
Foehrenbacher et al.
and hypoxic status in the bone marrow microenvironment. Nat Cell Biol (2013)
15:53343. doi:10.1038/ncb2730
51. Guise CP, Abbattista M, Singleton RS, Holford SD, Connolly J, Dachs GU,
et al. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. Cancer Res (2010) 70:157384.
doi:10.1158/0008-5472.CAN-09-3237
52. Houghton PJ, Lock R, Carol H, Morton CL, Phelps D, Gorlick R, et al. Initial
testing of the hypoxia activated prodrug PR-104 by the Pediatric Preclinical
Testing Program. Pediatr Blood Cancer (2011) 57:44353. doi:10.1002/pbc.
22921
53. Sun JD, Liu Q, Wang J, Ahluwalia D, Ferraro D, Wang Y, et al. Selective
tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor
growth in preclinical models of cancer. Clin Cancer Res (2012) 18:75870.
doi:10.1158/1078-0432.CCR-11-1980
54. Hicks KO, Pruijn FB, Secomb TW, Hay MP, Hsu R, Brown JM, et al. Use of
three-dimensional tissue cultures to model extravascular transport and predict
in vivo activity of hypoxia-targeted anticancer drugs. J Natl Cancer Inst (2006)
98:111828. doi:10.1093/jnci/djj306
55. Hicks KO. Introducing drug transport early in the design of hypoxia selective
anticancer agents using a mathematical modelling approach. In: DOnofrio A,
Cerrai P, Gandolfi A, editors. New Challenges for Cancer Systems Biomedicine.
Milan: Springer (2012). p. 33754. doi:10.1007/978-88-470-2571-4_18
56. Secomb TW, Hsu R, Park EY, Dewhirst MW. Greens function methods for
analysis of oxygen delivery to tissue by microvascular networks. Ann Biomed
Eng (2004) 32:151929. doi:10.1114/B:ABME.0000049036.08817.44
57. Pries AR, Cornelissen AJ, Sloot AA, Hinkeldey M, Dreher MR, Hoepfner M,
et al. Structural adaptation and heterogeneity of normal and tumor microvascular networks. PLoS Comput Biol (2009) 5:e1000394. doi:10.1371/journal.pcbi.
1000394
58. Secomb TW, Alberding JP, Hsu R, Dewhirst MW, Pries AR. Angiogenesis: an
adaptive dynamic biological patterning problem. PLoS Comput Biol (2013)
9:e1002983. doi:10.1371/journal.pcbi.1002983
59. Panthananickal A, Hansch C, Leo A. Structure-activity relationships in antitumor aniline mustards. J Med Chem (1978) 21:1626. doi:10.1021/jm00199a004
60. Helsby NA, Wheeler SJ, Pruijn FB, Palmer BD, Yang S, Denny WA, et al. Effect
of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: distinct mechanisms of bioreductive activation. Chem Res Toxicol
(2003) 16:46978. doi:10.1021/tx025662b
61. Gu Y, Guise CP, Patel K, Abbattista MR, Li J, Sun X, et al. Reductive metabolism
of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice. Cancer
Chemother Pharmacol (2011) 67:54355. doi:10.1007/s00280-010-1354-5
62. Gu Y, Atwell GJ, Wilson WR. Metabolism and excretion of the novel bioreductive prodrug PR-104 in mice, rats, dogs and humans. Drug Metab Dispos (2010)
38:498508. doi:10.1124/dmd.109.030973
63. Patel K, Lewiston D, Gu Y, Hicks KO, Wilson WR. Analysis of the hypoxiaactivated dinitrobenzamide mustard phosphate prodrug PR-104 and its alcohol metabolite PR-104A in plasma and tissues by liquid chromatography-mass
spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 856:30211.
doi:10.1016/j.jchromb.2007.06.035
64. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and
metabolic microenvironment of human tumors: a review. Cancer Res (1989)
49:644965.
65. Vaupel P. Tumor microenvironmental physiology and its implications for
radiation oncology. Semin Radiat Oncol (2004) 14:198206. doi:10.1016/j.
semradonc.2004.04.008
66. Wangsa-Wirawan ND, Linsenmeier RA. Retinal oxygen: fundamental and
clinical aspects. Arch Ophthalmol (2003) 121:54757. doi:10.1001/archopht.121.
4.547
67. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair
pathways as targets for cancer therapy. Nat Rev Cancer (2008) 8:193204.
doi:10.1038/nrc2342
68. Patterson AV, Donate F, Jamieson S, Thompson A, Lu GL, Lee HH, et al. Preclinical characterization of a novel hypoxia-activated irreversible pan-HER
inhibitor which induce complete responses in the H1975 xenograft model
[abstract]. J Thorac Oncol (2010) 5(6):S249S50.
69. Bagshawe KD. Antibody-directed enzyme/prodrug therapy (ADEPT). Biochem
Soc Trans (1990) 18:7502.
70. Bagshawe KD, Sharma SK, Springer CJ, Rogers GT. Antibody directed enzyme
prodrug therapy (ADEPT). A review of some theoretical, experimental and clinical aspects. Ann Oncol (1994) 5:87991.
71. Hay MP, Pchalek K, Pruijn FB, Hicks KO, Siim BG, Anderson RF, et al. Hypoxiaselective 3-alkyl 1,2,4-benzotriazine 1,4-dioxides: the influence of hydrogen
bond donors on extravascular transport and antitumor activity. J Med Chem
(2007) 50:665464. doi:10.1021/jm701037w
72. Dedrick RL, Flessner MF. Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst (1997)
89:4807. doi:10.1093/jnci/89.7.480
73. Wilson WR, Pullen SM, Hogg A, Helsby NA, Hicks KO, Denny WA. Quantitation of bystander effects in nitroreductase suicide gene therapy using threedimensional cell cultures. Cancer Res (2002) 62:142532.
74. Atwell GJ, Yang S, Pruijn FB, Pullen SM, Hogg A, Patterson AV, et al. Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5 mustards as
prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy. J Med Chem
(2007) 50:1197212. doi:10.1021/jm061062o
75. Butler J, Hoey BM. The one-electron reduction potential of several substrates
can be related to their reduction rates by cytochrome P-450 reductase. Biochim
Biophys Acta (1993) 1161:738. doi:10.1016/0167-4838(93)90198-Z
76. Cenas N, Anusevicius Z, Bironaite D, Bachmanova GI, Archakov AI, Ollinger
K. The electron transfer reactions of NADPH: cytochrome P450 reductase with
nonphysiological oxidants. Arch Biochem Biophys (1994) 315:4006.
77. Pruijn FB, Patel K, Hay MP, Wilson WR, Hicks KO. Prediction of tumour tissue diffusion coefficients of hypoxia-activated prodrugs from physicochemical
parameters. Aust J Chem (2008) 61:68793. doi:10.1071/CH08240
78. Gillies RJ, Schornack PA, Secomb TW, Raghunand N. Causes and effects of heterogeneous perfusion in tumors. Neoplasia (1999) 1:197207. doi:10.1038/sj.
neo.7900037
79. Moreno-Merlo F, Nicklee T, Hedley DW. Association between tissue hypoxia and
elevated non-protein sulphydryl concentrations in human cervical carcinoma
xenografts. Br J Cancer (1999) 81:98993. doi:10.1038/sj.bjc.6690797
80. Vukovic V, Nicklee T, Hedley DW. Multiparameter fluorescence mapping of
nonprotein sulfhydryl status in relation to blood vessels and hypoxia in cervical carcinoma xenografts 10. Int J Radiat Oncol Biol Phys (2002) 52:83743.
doi:10.1016/S0360-3016(01)02716-X
81. Cardenas-Navia LI, Mace D, Richardson RA, Wilson DF, Shan S, Dewhirst MW.
The pervasive presence of fluctuating oxygenation in tumors. Cancer Res (2008)
68:58129. doi:10.1158/0008-5472.CAN-07-6387
82. Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate
angiogenesis and radiotherapy response. Nat Rev Cancer (2008) 8:42537.
doi:10.1038/nrc2397
83. Dewhirst MW. Relationships between cycling hypoxia, HIF-1, angiogenesis and
oxidative stress. Radiat Res (2009) 172:65365. doi:10.1667/RR1926.1
84. Dewhirst MW, Kimura H, Rehmus SW, Braun RD, Papahadjopoulos D, Hong
K, et al. Microvascular studies on the origins of perfusion-limited hypoxia.
Br J Cancer Suppl (1996) 27:S24751.
85. Kimura H, Braun RD, Ong ET, Hsu R, Secomb TW, Papahadjopoulos D, et al.
Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia
and reoxygenation in tumor parenchyma. Cancer Res (1996) 56:55228.
86. Lanzen J, Braun RD, Klitzman B, Brizel D, Secomb TW, Dewhirst MW. Direct
demonstration of instabilities in oxygen concentrations within the extravascular compartment of an experimental tumor. Cancer Res (2006) 66:221923.
doi:10.1158/0008-5472.CAN-03-2958
87. Patterson LH, McKeown SR. AQ4N: a new approach to hypoxia-activated cancer
chemotherapy. Br J Cancer (2000) 83:158993. doi:10.1054/bjoc.2000.1564
88. Tietze LF, Schmuck K. Prodrugs for targeted tumor therapies: recent developments in ADEPT, GEPT and PMT. Curr Pharm Des (2011) 17:352747.
doi:10.2174/138161211798194459
89. Griffiths L, Binley K, Iqball S, Kan O, Maxwell P, Ratcliffe P, et al. The
macrophage a novel system to deliver gene therapy to pathological hypoxia.
Gene Ther (2000) 7:25562. doi:10.1038/sj.gt.3301058
90. Ahn GO, Brown M. Targeting tumors with hypoxia-activated cytotoxins. Front
Biosci (2007) 12:3483501. doi:10.2741/2329
91. Carlson DJ, Keall PJ, Loo BW Jr., Chen ZJ, Brown JM. Hypofractionation
results in reduced tumor cell kill compared to conventional fractionation for
tumors with regions of hypoxia. Int J Radiat Oncol Biol Phys (2011) 79:118895.
doi:10.1016/j.ijrobp.2010.10.007
Foehrenbacher et al.
92. Patel K, Choy SF, Hicks KO, Melink TJ, Holford NHG, Wilson WR. A combined
pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans,
dogs, rats and mice predicts species differences in clearance and toxicity. Cancer
Chemother Pharmacol (2011) 67:114555. doi:10.1007/s00280-010-1412-z
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 06 November 2013; paper pending published: 26 November 2013; accepted:
11 December 2013; published online: 27 December 2013.
www.frontiersin.org